Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: Effects of antihypertensive therapy

S. K. Nadar, A. D. Blann, Gregory Y H Lip

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background. Platelets carry angiogenic growth factors vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1). Although platelet-derived growth factors are important in the pathogenesis and metastasis of malignancy, their role in the pathogenesis of complications and the response to treatment in hypertension is less known. Objective. To test the hypotheses that there are differences in VEGF and Ang-1 in the plasma and within platelets from patients with hypertension, and that levels change with successful treatment. Methods. We recruited 42 previously untreated patients with hypertension (25 male; mean age 53 years) and 30 age- and sex-matched controls. Plasma VEGF, Ang-1 and soluble P-selectin (sPsel, an index of platelet activation), and total platelet [platelet VEGF (pVEGF) and platelet Ang-1 (pAng-1)] were measured by ELISA. The patients were then treated for 6 months with amlodipine-based antihypertensive therapy, achieving a mean blood pressure below 140/80 mmHg. Results. Patients with hypertension had significantly higher levels of plasma sPsel (P = 0.01), VEGF (P < 0.001) and Ang-1 (P = 0.01), as well as pVEGF (P < 0.001) and pAng-1 (P = 0.02). The levels of plasma and platelet angiogenic growth factors were significantly reduced after antihypertensive treatment (VEGF, P = 0.01; pVEGF, P < 0.001; Ang-1, P < 0.001; pAng-1, P = 0.04). There were no correlations with blood pressure or the levels of sPsel. Conclusion. Levels of plasma and intra-platelet VEGF and Ang-1 are increased in hypertension and are decreased with treatment. Platelet levels of VEGF and Ang-1 may be related to platelet activation but may also involve other mechanisms (for example, the general vascular and haemodynamic changes) that are seen in hypertension.

Original languageEnglish
Pages (from-to)331-337
Number of pages7
JournalJournal of Internal Medicine
Volume256
Issue number4
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Angiopoietin-1
Antihypertensive Agents
Vascular Endothelial Growth Factor A
Blood Platelets
Hypertension
Therapeutics
Angiogenesis Inducing Agents
Platelet Activation
Intercellular Signaling Peptides and Proteins
Blood Pressure
Amlodipine
P-Selectin
Platelet-Derived Growth Factor
Blood Vessels

Keywords

  • Angiopoietin-1
  • Calcium channel blockers
  • Hypertension
  • P-selectin
  • Platelet
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension : Effects of antihypertensive therapy. / Nadar, S. K.; Blann, A. D.; Lip, Gregory Y H.

In: Journal of Internal Medicine, Vol. 256, No. 4, 10.2004, p. 331-337.

Research output: Contribution to journalArticle

@article{40a6bbc0b9094d13b8902fc583088416,
title = "Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: Effects of antihypertensive therapy",
abstract = "Background. Platelets carry angiogenic growth factors vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1). Although platelet-derived growth factors are important in the pathogenesis and metastasis of malignancy, their role in the pathogenesis of complications and the response to treatment in hypertension is less known. Objective. To test the hypotheses that there are differences in VEGF and Ang-1 in the plasma and within platelets from patients with hypertension, and that levels change with successful treatment. Methods. We recruited 42 previously untreated patients with hypertension (25 male; mean age 53 years) and 30 age- and sex-matched controls. Plasma VEGF, Ang-1 and soluble P-selectin (sPsel, an index of platelet activation), and total platelet [platelet VEGF (pVEGF) and platelet Ang-1 (pAng-1)] were measured by ELISA. The patients were then treated for 6 months with amlodipine-based antihypertensive therapy, achieving a mean blood pressure below 140/80 mmHg. Results. Patients with hypertension had significantly higher levels of plasma sPsel (P = 0.01), VEGF (P < 0.001) and Ang-1 (P = 0.01), as well as pVEGF (P < 0.001) and pAng-1 (P = 0.02). The levels of plasma and platelet angiogenic growth factors were significantly reduced after antihypertensive treatment (VEGF, P = 0.01; pVEGF, P < 0.001; Ang-1, P < 0.001; pAng-1, P = 0.04). There were no correlations with blood pressure or the levels of sPsel. Conclusion. Levels of plasma and intra-platelet VEGF and Ang-1 are increased in hypertension and are decreased with treatment. Platelet levels of VEGF and Ang-1 may be related to platelet activation but may also involve other mechanisms (for example, the general vascular and haemodynamic changes) that are seen in hypertension.",
keywords = "Angiopoietin-1, Calcium channel blockers, Hypertension, P-selectin, Platelet, Vascular endothelial growth factor",
author = "Nadar, {S. K.} and Blann, {A. D.} and Lip, {Gregory Y H}",
year = "2004",
month = "10",
doi = "10.1111/j.1365-2796.2004.01367.x",
language = "English",
volume = "256",
pages = "331--337",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension

T2 - Effects of antihypertensive therapy

AU - Nadar, S. K.

AU - Blann, A. D.

AU - Lip, Gregory Y H

PY - 2004/10

Y1 - 2004/10

N2 - Background. Platelets carry angiogenic growth factors vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1). Although platelet-derived growth factors are important in the pathogenesis and metastasis of malignancy, their role in the pathogenesis of complications and the response to treatment in hypertension is less known. Objective. To test the hypotheses that there are differences in VEGF and Ang-1 in the plasma and within platelets from patients with hypertension, and that levels change with successful treatment. Methods. We recruited 42 previously untreated patients with hypertension (25 male; mean age 53 years) and 30 age- and sex-matched controls. Plasma VEGF, Ang-1 and soluble P-selectin (sPsel, an index of platelet activation), and total platelet [platelet VEGF (pVEGF) and platelet Ang-1 (pAng-1)] were measured by ELISA. The patients were then treated for 6 months with amlodipine-based antihypertensive therapy, achieving a mean blood pressure below 140/80 mmHg. Results. Patients with hypertension had significantly higher levels of plasma sPsel (P = 0.01), VEGF (P < 0.001) and Ang-1 (P = 0.01), as well as pVEGF (P < 0.001) and pAng-1 (P = 0.02). The levels of plasma and platelet angiogenic growth factors were significantly reduced after antihypertensive treatment (VEGF, P = 0.01; pVEGF, P < 0.001; Ang-1, P < 0.001; pAng-1, P = 0.04). There were no correlations with blood pressure or the levels of sPsel. Conclusion. Levels of plasma and intra-platelet VEGF and Ang-1 are increased in hypertension and are decreased with treatment. Platelet levels of VEGF and Ang-1 may be related to platelet activation but may also involve other mechanisms (for example, the general vascular and haemodynamic changes) that are seen in hypertension.

AB - Background. Platelets carry angiogenic growth factors vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1). Although platelet-derived growth factors are important in the pathogenesis and metastasis of malignancy, their role in the pathogenesis of complications and the response to treatment in hypertension is less known. Objective. To test the hypotheses that there are differences in VEGF and Ang-1 in the plasma and within platelets from patients with hypertension, and that levels change with successful treatment. Methods. We recruited 42 previously untreated patients with hypertension (25 male; mean age 53 years) and 30 age- and sex-matched controls. Plasma VEGF, Ang-1 and soluble P-selectin (sPsel, an index of platelet activation), and total platelet [platelet VEGF (pVEGF) and platelet Ang-1 (pAng-1)] were measured by ELISA. The patients were then treated for 6 months with amlodipine-based antihypertensive therapy, achieving a mean blood pressure below 140/80 mmHg. Results. Patients with hypertension had significantly higher levels of plasma sPsel (P = 0.01), VEGF (P < 0.001) and Ang-1 (P = 0.01), as well as pVEGF (P < 0.001) and pAng-1 (P = 0.02). The levels of plasma and platelet angiogenic growth factors were significantly reduced after antihypertensive treatment (VEGF, P = 0.01; pVEGF, P < 0.001; Ang-1, P < 0.001; pAng-1, P = 0.04). There were no correlations with blood pressure or the levels of sPsel. Conclusion. Levels of plasma and intra-platelet VEGF and Ang-1 are increased in hypertension and are decreased with treatment. Platelet levels of VEGF and Ang-1 may be related to platelet activation but may also involve other mechanisms (for example, the general vascular and haemodynamic changes) that are seen in hypertension.

KW - Angiopoietin-1

KW - Calcium channel blockers

KW - Hypertension

KW - P-selectin

KW - Platelet

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=4644234870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644234870&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2796.2004.01367.x

DO - 10.1111/j.1365-2796.2004.01367.x

M3 - Article

C2 - 15367176

AN - SCOPUS:4644234870

VL - 256

SP - 331

EP - 337

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 4

ER -